Last quarter (Q4 2023), Teva Pharmaceutical's total revenue was $4.46B, an increase of 14.78% from the same quarter last year. In Q4, Teva Pharmaceutical's net income was $429.00M. See Teva Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 15.85B	$ 15.85B	$ 14.93B	$ 15.88B	$ 16.66B	$ 16.89B
Cost of Revenue	$ 8.20B	$ 8.20B	$ 7.95B	$ -8.28B	$ 8.93B	$ 9.35B
Gross Profit	$ 7.65B	$ 7.65B	$ 6.97B	$ 7.59B	$ 7.73B	$ 7.54B
Operating Expense	$ 3.31B	$ 2.29B	$ -4.28B	$ 5.88B	$ 4.67B	$ 4.79B
Operating Income	$ 2.38B	$ 433.00M	$ 2.69B	$ 1.72B	$ 3.06B	$ 2.74B
Net Non Operating Interest Income Expense	$ -1.29B	$ -1.03B	$ -991.00M	$ -1.06B	$ -963.00M	$ -877.00M
Other Income Expense	$ 104.00M	$ 1.05B	$ 4.76B	$ -9.00M	$ -6.50B	$ -3.13B
Pretax Income	$ -624.00M	$ -624.00M	$ -3.06B	$ 658.00M	$ -4.41B	$ -1.26B
Tax Provision	$ -7.00M	$ -7.00M	$ -638.00M	$ 211.00M	$ -168.00M	$ -278.00M
Earnings From Equity Interest Net Of Tax	$ 2.00M	$ 2.00M	-	$ 9.00M	$ 138.00M	$ -13.00M
Net Income Common Stockholders	$ 253.00M	$ 3.66B	$ -2.35B	$ 416.00M	$ -3.99B	$ -999.00M
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 11.51B	$ 10.49B	$ 9.28B	$ -2.40B	$ 13.60B	$ 14.14B
Net Income From Continuing And Discontinued Operation	$ -592.00M	$ -559.00M	$ -2.35B	$ 416.00M	$ -3.99B	$ -999.00M
Normalized Income	$ 1.73B	$ 2.09B	$ 1.02B	-	$ 2.26B	$ 1.38B
Interest Expense	-	-	-	-	$ 963.00M	$ 881.00M
EBIT	$ 665.00M	$ 405.00M	$ -2.13B	$ 1.72B	$ -3.44B	$ -384.00M
EBITDA	$ 1.82B	$ 1.56B	$ -827.00M	$ 3.05B	$ -1.89B	$ 1.34B

Currency in USD

Teva Pharmaceutical Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing